Nexpoint Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Nexpoint Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-62,591	Closed	-$2.16M	–	194
2020 Q3	$2.16M	Buy	+62,591	New	+$1.33M	0.49%	36
2020 Q1	–	Sell	-24,300	Closed	-$813K	–	314
2019 Q4	$813K	Hold	24,300	–	–	0.06%	150
2019 Q3	$509K	Buy	+24,300	New	+$496K	0.03%	248

Nexpoint Asset Management's AIMT Position: Q4 2020 in Review

Nexpoint Asset Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 62,591 shares — an estimated $2.16M sold.

Nexpoint Asset Management first reported a position in AIMT in Q3 2019 and held it in 3 quarters. The position peaked at $2.16M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Nexpoint Asset Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Nexpoint Asset Management sold 62,591 Aimmune Therapeutics shares in Q4 2020, an estimated $2.16M.
Nexpoint Asset Management first reported a position in Aimmune Therapeutics in Q3 2019 and held it in 3 quarters.
Nexpoint Asset Management's Aimmune Therapeutics position peaked at $2.16M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Nexpoint Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.